GSK PLC Stock Price, News & Analysis

Eli Lilly (LLY), Vir Biotechnology (VIR), and GlaxoSmithKline (GSK) announced a collaboration to evaluate the combination of their COVID-19 therapies in low-risk patients with mild to moderate COVID-19. The expanded BLAZE-4 trial will assess bamlanivimab (700mg) with VIR-7831 (500mg), both neutralizing antibodies targeting SARS-CoV-2. This marks the first cross-company monoclonal antibody collaboration. Bamlanivimab is authorized for emergency use, while VIR-7831 is investigational. The trial aims to determine if this combination therapy can improve treatment outcomes.

Eligo Bioscience has signed a research and option agreement with GlaxoSmithKline (GSK) to advance its breakthrough treatment, EB005, targeting acne vulgaris through CRISPR-based technology. Eligo will receive an upfront payment and funding to progress EB005 until preclinical proof of concept. If GSK opts in, Eligo could earn up to $224 million in fees and milestone payments, plus royalties on sales. The partnership aims to address acne's root causes by selectively modulating the skin's microbiome, potentially changing treatment paradigms in the industry.

GSK has received FDA approval for BENLYSTA (belimumab) to treat adult patients with active lupus nephritis (LN) in conjunction with standard therapy. This marks a significant advancement as BENLYSTA is the first approved medication for this condition in over 50 years. The approval, based on the successful BLISS-LN study, showed 43% of patients treated with BENLYSTA achieved Primary Efficacy Renal Response compared to 32% with placebo. The treatment aims to improve renal outcomes and delay kidney replacement therapies, addressing a critical need in the lupus community.

GSK Consumer Healthcare has launched Robitussin Naturals, its first drug-free line aimed at relieving occasional coughs. As the leading cough relief brand, Robitussin leverages over 70 years of experience to introduce these new dietary supplements formulated with natural ingredients like True Source certified honey and English ivy. The brand has partnered with cheer coach Monica Aldama to promote these products, emphasizing their appeal to health-conscious consumers. Robitussin Naturals products are now available in drugstores nationwide.

ViiV Healthcare announced the launch of a new weekly podcast titled Being Seen, which explores cultural representations relevant to the queer and gay Black male experience. Hosted by Darnell Moore, the podcast aims to change perceptions and reduce stigma surrounding this community, emphasizing their stories and challenges. Available starting October 6, Being Seen features conversations with various artists and activists. This initiative aligns with ViiV's focus on addressing HIV-related disparities and amplifying marginalized voices in society.

GSK Consumer Healthcare has launched Advil Dual Action, a groundbreaking over-the-counter pain relief formula that combines ibuprofen and acetaminophen, becoming the first FDA-approved of its kind in 25 years. This innovative product targets pain through two mechanisms: directly at the source and by blocking pain signals to the brain. Acclaimed actress Angela Kinsey is the face of the launch, aiming to showcase its efficacy in managing everyday aches and pains. A survey reveals 95% of adults experience pain, with 80% seeking better relief options, highlighting significant market potential for Advil Dual Action.

GSK Consumer Healthcare launched Advil Dual Action, an innovative over-the-counter pain relief solution combining ibuprofen and acetaminophen. This launch follows FDA approval, marking a significant milestone as the first product of its kind in the OTC market. A recent survey revealed that while 95% of Americans experience pain, 80% do not find complete relief with existing medications. Advil aims to enhance pain management discussions with a modern emoji scale for pain representation. Advil Dual Action is available online and in stores nationwide.

On July 14, 2020, GlaxoSmithKline (GSK) announced that the FDA Oncologic Drugs Advisory Committee voted 12-0 in favor of the benefit-risk profile of belantamab mafodotin, an investigational treatment for relapsed or refractory multiple myeloma. The committee recognized its potential for patients who have undergone at least four prior therapies. The recommendation stems from the DREAMM-2 clinical trial. While the FDA may consider this recommendation, it is not obliged to follow it. Belantamab mafodotin is not yet approved worldwide.